search

New Project to Improve Diagnosis and Treatment of Ovarian Cancer

New Project to Improve Diagnosis and Treatment of Ovarian Cancer
27/02/2019

Porvair Sciences reports on its involvement in a new £2.6 million project* led by Swansea University (UK) that aims to dramatically improve the diagnosis and treatment of ovarian cancer**.

This project will involve collaboration with 5 key industrial partners - Porvair Sciences, Bruker UK, GE Healthcare UK, Axis Bio and GlaxoSmithKline (GSK). A new Antibody Drug Conjugates company will join the project in its second year. Antibody Drug Conjugates (ADC’s) are a powerful new class of therapeutics in medical oncology, where antibodies that target specific cancers are coupled with cytotoxic agents. The Cluster for Epigenomic and Antibody Drug Conjugate Therapeutics (CEAT) project aims to utilise novel epigenetic drugs and ADC’s to manipulate chemical compounds thus creating a new route for the treatment of ovarian cancer.

Utilizing its proprietary Chromatrap® bead-free Chromatin Immunoprecipitation (ChIP) technology - Porvair Sciences will develop new epigenomic profiling approaches that will deliver the required advances in cutting-edge drug development and patient profiling. Using the Chromatrap® technology, Porvair Sciences will work with Swansea University and industrial partners to identify and characterise epigenetic drugs that are effective in preventing cancer development in ovarian cancer models. In addition, Porvair Sciences will support the evaluation of the Antibody Drug Conjugates (ADCs) resulting from the CEAT project.

CEAT principal investigator - Dr. Lewis Francis from Swansea University’s School of Medicine commented “Epigenetics involves chemical changes to the DNA and associated proteins that can lead to genes being turned on or off. In some cases, this can go wrong and lead to disease. Through the CEAT project, Swansea University will work closely with CEAT partners to develop drugs that can control epigenetic signals; these epigenetic drugs can be targeted specifically towards ovarian cancer cells where epigenetic changes have occurred.”

Amy Johnson, Business and Technical Development Manager at Porvair Sciences commented “We are delighted to be involved with the CEAT project. This is a great opportunity for the project to leverage our bead-free ChIP technology and expertise to be at the forefront of developing epigenetic-based cancer therapies”

Enquiry Form



More News

Solvent Dry-Down for LC/MS Sample Preparation

Solvent Dry-Down for LC/MS Sample Preparation

Porvair Sciences has posted a new online video demonstrating how nitrogen blowdown evaporators offer a useful tool for removing the solvent dry-down b...

Read More
Porvair Sciences Announces 2012 Microplate Catalogue

Porvair Sciences Announces 2012 Microplate Catalogue

Many scientists around the world have come to rely upon the Porvair Sciences Catalogue as a primary source of information that enables them to choose ...

Read More
Compact Electronic Pipette Filler Perfect for Fumehood Use

Compact Electronic Pipette Filler Perfect for Fumehood Use

Compact in size, the UltraJet electronic pipette filler from Porvair Sciences is perfect for use even in confined spaces such as safety cabinets and f...

Read More

Read More

Read More

List your business

Would you like to register your company on one of the UK's largest and most effective Trade websites?

Are you looking for a reliable and consistent source of enquiries from your industry sector? Would you like to see why Find the Needle clients come back year after year to use our service? If so then feel free to register using the link 'here'.

Register
Office Address: